Concepedia

Kras-targeted Therapy

KRAS-Targeted Therapy is a therapeutic strategy in oncology that specifically inhibits the oncogenic KRAS signaling pathway in thoracic malignancies, distinguishing it from broader cytotoxic or non-selective kinase inhibition approaches.

895

Publications

83.2K

Citations

8.3K

Authors

1.8K

Institutions

Publications per year

2017–2026

555

Parents

Publications

895

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

Jude Canon, Karen Rex, Anne Y. Saiki et al. · Nature · 2019 · 2.3K citations

, , +14

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations

, , +13

Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism

Haoqiang Ying, Alec C. Kimmelman, Costas A. Lyssiotis et al. · Cell · 2012 · 2K citations · Full text

, , +11

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Sandra Misale, Rona Yaeger, Sebastijan Hobor et al. · Nature · 2012 · 1.9K citations · Full text

, , +16

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor <i>KRAS</i> and <i>BRAF</i> Mutation Status

Eric Van Cutsem, Claus-Henning Köhne, István Láng et al. · Journal of Clinical Oncology · 2011 · 1.9K citations · Full text

, , +17

1–5 of 895

Authors

8.3K

  1. PA
    Pasi A. Jänne

    Dana-Farber Cancer Institute, United States

    34 publications · 6.8K citations

    27

    h-index

  2. JG
    James G. Christensen

    Pfizer (United States), United States

    22 publications · 5.7K citations

    21

    h-index

  3. AI
    Alexander I. Spira

    Virginia Cancer Specialists, United States

    22 publications · 4.4K citations

    20

    h-index

  4. KW
    Kwok‐Kin Wong

    Dana-Farber Cancer Institute, United States

    19 publications · 3.5K citations

    18

    h-index

  5. EV
    Eric Van Cutsem

    KU Leuven, Belgium

    18 publications · 7.7K citations

    16

    h-index

1–5 of 8.3K

Institutions

1.8K

  1. Dana-Farber Cancer Institute

    Boston, United States

    49 h-index

    384 publications

    101.1K citations

  2. The University of Texas MD Anderson Cancer Center

    Houston, United States

    45 h-index

    515 publications

    111K citations

  3. Memorial Sloan Kettering Cancer Center

    New York, United States

    44 h-index

    389 publications

    160.1K citations

  4. Harvard University

    Cambridge, United States

    43 h-index

    328 publications

    61.6K citations

  5. Massachusetts General Hospital

    Boston, United States

    34 h-index

    260 publications

    47.6K citations

  6. Sarah Cannon

    Nashville, United States

    31 h-index

    50 publications

    8.9K citations

  7. Amgen (United States)

    Thousand Oaks, United States

    25 h-index

    191 publications

    85.9K citations

  8. Mirati Therapeutics (United States)

    San Diego, United States

    25 h-index

    166 publications

    58.1K citations

1–8 of 1.8K

Venues

  1. Journal of Clinical Oncology

    77 publications · 7.6K citations

    35

    h-index

  2. Cancer Research

    44 publications · 2.3K citations

    29

    h-index

  3. Cancer Discovery

    27 publications · 6.7K citations

    26

    h-index

  4. Annals of Oncology

    42 publications · 2.1K citations

    26

    h-index

  5. Oncogene

    22 publications · 1.7K citations

    22

    h-index

1–5